Dasatinib

Treats newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia…. Sold as Sprycel, Phyrago. Every FDA application for this active ingredient: 3 branded and 10 generic.

As of Nov 14, 2026, FDA lists 13 applications for Dasatinib (sold as Sprycel, Phyrago), first approved Jun 28, 2006, with 10 new uses approved and 0 published complete response letters.

• First approved: Jun 28, 2006
• Applications: 13
• New uses approved: 10
• Complete response letters: 0
• Medicare spending, 2025: $531M
• First approved in the EU: Nov 20, 2006
• First approved in Japan: Jan 21, 2009